

IN THE CLAIMS

1-34. (Canceled)

35. (Currently Amended) A composition for generating an immune response to a prostate tumor-associated antigen in a human subject, comprising:

~~a proliferation-incompetent cell comprising GM-CSF-expressing proliferation-incompetent cell~~ a nucleic acid encoding said prostate tumor-associated antigen, wherein when said prostate tumor-associated antigen is expressed, by said proliferation-incompetent cell in the presence of GM-CSF, wherein said proliferation-incompetent cell is selected from the group consisting of LnCaP, PC3 and DU145, wherein said composition is capable of eliciting a humoral immune response ~~is detected, said humoral immune response not detected when said prostate tumor-associated antigen is expressed by said proliferation-incompetent cell in the absence of GM-CSF and wherein said~~ to a prostate tumor-associated antigen ~~[[has]]~~ with a molecular weight selected from the group consisting of 250 kD, 160 kD, 150 kD, 31 kD, 26 kD and 14 kD, as ~~determined~~ detected by SDS-PAGE, wherein said humoral immune response is not detected in said human subject prior to administering said composition and said prostate tumor-associated antigen does not cross-react immunologically with prostate-specific antigen.

36. (Currently Amended) The composition of Claim 35, wherein said proliferation-incompetent cell is ~~autologous~~ an LnCaP cell.

37. (Currently Amended) The composition of Claim 35, wherein said proliferation-incompetent cell is ~~allogeneic~~ a PC3 cell.

38. (Currently Amended) The composition of Claim 35, wherein said ~~GM-CSF is expressed by the same cell that expresses said prostate tumor-associated antigen~~ proliferation-incompetent cell is a DU145 cell.

39. (Currently Amended) The composition of Claim ~~[[35]]~~ 36, ~~wherein said prostate tumor-associated antigen has a molecular weight of 250 kD~~ further comprising a proliferation-incompetent PC3 cell.

40. (Currently Amended) The composition of Claim 35, wherein said ~~proliferation-incompetent cell is a prostate cell~~ prostate tumor-associated antigen has a molecular weight of 250 kD.

41- 43. (Canceled)

44. (New) The composition of Claim 39, wherein said LnCaP and PC3 cells are administered to said human subject in equal doses.

45. (New) The composition of Claim 44, wherein said dose of LnCaP and PC3 cells is 6×10^7 cells per cell type.

46. (New) The composition of Claim 39, wherein said LnCaP and PC3 cells are administered subcutaneously.

47. (New) The composition of Claim 39, wherein said LnCaP and PC3 cells express 200-300 ng GM-CSF per 10^6 cells.

48. (New) A method for generating an immune response to a prostate tumor-associated antigen, comprising:

administering to a human subject a GM-CSF-expressing proliferation-incompetent cell selected from the group consisting of LnCaP, PC3 and DU145, wherein a humoral immune response to a prostate tumor-associated antigen with a molecular weight selected from the group consisting of 250 kD, 160 kD, 150 kD, 31 kD, 26 kD and 14 kD, is detected by SDS-PAGE subsequent to said administering, wherein said humoral immune response is not detected in said human subject by said SDS-PAGE prior to said administering and said prostate tumor-associated antigen does not cross-react immunologically with prostate-specific antigen.

49. (New) The method of Claim 48, wherein said proliferation-incompetent cell is an LnCaP cell.
50. (New) The method of Claim 48, wherein said proliferation-incompetent cell is a PC3 cell.
51. (New) The method of Claim 48, wherein said proliferation-incompetent cell is a DU145 cell.
52. (New) The method of Claim 49, further comprising a proliferation-incompetent PC3 cell.
53. (New) The method of Claim 48, wherein said prostate tumor-associated antigen has a molecular weight of 250 kD.
54. (New) The method of Claim 52, wherein said LnCaP and PC3 cells are administered to said human subject in equal doses.
55. (New) The method of Claim 54, wherein said dose of LnCaP and PC3 cells is 6×10^7 cells per cell type.
56. (New) The method of Claim 52, wherein said LnCaP and PC3 cells are administered subcutaneously.
57. (New) The method of Claim 52, wherein said LnCaP and PC3 cells express 200-300 ng GM-CSF per 10^6 cells.